Hengdian Group Capital (HgC)

Founded in 2017, HgC is the investment and corporate development arm of Hengdian Group, managing over $350 million USD in assets. As strategic and financial investors, our focus spans smart manufacturing & renewables, biotech & medtech, and film & consumer sectors. We utilize resources from the public companies under Hengdian Group to provide unmatched support and value-add to startups. Our tight-knit collaboration with these companies not only fortifies our investment strategy but also streamlines and enhances the mergers & acquisitions process for the entire group. At our core, we're committed to propelling ventures that usher in growth and innovation. Some of our notable investments are Zelgen Pharma (SSE: 688266), Weihua New Material (SSE: 603310), Xunce Technology, Corxel etc.